Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.07
-0.0500-0.82%
Post-market: 6.140.0700+1.15%19:09 EDT
Volume:1.43M
Turnover:8.72M
Market Cap:723.21M
PE:-13.65
High:6.24
Open:6.12
Low:5.98
Close:6.12
Loading ...

Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)

TIPRANKS
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Primo Brands, Cracker Barrel, Redfin

Reuters
·
10 Mar

Recession Fears Drive Premarket Losses for US Equity

MT Newswires Live
·
10 Mar

Top Premarket Gainers

MT Newswires Live
·
10 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Airbnb, Beacon, Redfin

Reuters
·
10 Mar

Trevi Therapeutics Says Phase 2a Haduvio Trial Shows Significant Reduction in Cough Count

MT Newswires Live
·
10 Mar

Trevi Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Mar

Trevi Therapeutics Inc : Needham Raises Target Price to $25 From $8

THOMSON REUTERS
·
10 Mar

BUZZ-Trevi jumps as chronic cough therapy succeeds mid-stage trial

Reuters
·
10 Mar

Trevi Therapeutics Shares up 21.6% Premarket as Cough Therapy Succeeds in Mid-Stage Trial

THOMSON REUTERS
·
10 Mar

BRIEF-Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC

Reuters
·
10 Mar

Trevi Therapeutics: Patient Reported & Other Secondary Outcomes Were Statistically Significant & Consistent With Primary Endpoint

THOMSON REUTERS
·
10 Mar

Trevi Therapeutics: Announce Positive Topline Results From Its Phase 2a River Trial of Haduvio for Treatment of Patients With Rcc (N=66)

THOMSON REUTERS
·
10 Mar

Trevi Therapeutics Inc: Haduvio Met Primary Endpoint

THOMSON REUTERS
·
10 Mar

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire
·
10 Mar

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

PR Newswire
·
10 Mar

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

PR Newswire
·
27 Feb

B.Riley Financial Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

TIPRANKS
·
26 Feb

BRIEF-Trevi Therapeutics Completes Enrollment For Phase 2B Coral Trial

Reuters
·
25 Feb

Trevi Therapeutics Completes Enrollment for Phase 2B Coral Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough

THOMSON REUTERS
·
25 Feb